Scientists have pinpointed how the buildup of fumarate, a metabolic waste product, disrupts the body's ability to fix damaged DNA in a rare form of kidney cancer. A study published in Cancer & Metabolism by researchers led by Nian Liu shows that elevated fumarate levels chemically alter a crucial DNA repair protein, triggering genetic instability in fumarate hydratase-deficient renal cell carcinoma (FH-dRCC). The work establishes a direct connection between faulty metabolism and the breakdown of cellular defenses against genetic damage.
The research team tested both normal and FH-mutant kidney cells by exposing them to ionizing radiation and hydroxyurea to trigger DNA damage and replication stress. While CHK2 activation stayed normal in the mutant cells, CHK1 activation was significantly weakened, especially in UOK268 cells. When healthy cells were dosed with dimethyl fumarate—a compound mimicking fumarate's biological effects—CHK1 activation dropped similarly. Restoring working FH enzyme to mutant cells brought CHK1 phosphorylation back to normal levels. In functional tests, radiation caused a twofold jump in the share of healthy cells pausing at the G2/M cell cycle checkpoint, but FH-mutant cells showed no meaningful increase, signaling a broken arrest mechanism. Using liquid chromatography-tandem mass spectrometry, the team identified 930 proteins that had been succinated in UOK268 cells, including replication protein A1 (RPA1), which binds to single-stranded DNA and recruits the ATR-CHK1 machinery.
The authors report that fumarate chemically modifies RPA1 by attaching to cysteine residues at positions 481 and 486, both located in a zinc finger-like region critical for stabilizing RPA1's DNA-binding domain. Electrophoretic mobility shift assays showed that this succination sharply reduced RPA1's ability to latch onto single-stranded DNA. According to the study, this structural disruption stops RPA1 from properly coating single-stranded DNA, the signal needed to recruit ATR, ATRIP, and TOPBP1 to kick off the checkpoint response. The research also found that homologous recombination efficiency plummeted in cells treated with dimethyl fumarate or FH inhibitors, suggesting that fumarate accumulation cripples the cell's capacity to mend double-strand breaks.
The report explains that FH-dRCC arises from inherited mutations that knock out fumarate hydratase, an enzyme essential to the tricarboxylic acid cycle, causing fumarate to pile up inside cells. This excess fumarate acts as an oncometabolite—a cancer-promoting molecule—by chemically reacting with cysteine residues on proteins through succination, forming stable 2-succino-cysteine adducts. When RPA1 is succinated at its DNA-binding domain, it can't effectively coat single-stranded DNA at sites of replication stress or damage, blocking the recruitment of proteins that activate the ATR-CHK1 pathway. Without proper ATR-CHK1 signaling, cells fail to arrest at the G2/M checkpoint, skipping the pause needed for DNA repair and allowing mutations to accumulate. This cascade links a metabolic defect directly to genome instability, revealing how the loss of a metabolic enzyme drives aggressive tumor growth by sabotaging DNA repair systems. The authors acknowledge that while they observed RPA1 succination in lab conditions, they couldn't detect it in purified RPA1 from mutant cells using mass spectrometry, possibly due to low abundance or technical challenges.
The findings highlight a vulnerability in FH-deficient kidney cancers that could open doors for targeted treatments aimed at the metabolic flaws fueling tumor aggression. By showing that an oncometabolite can directly cripple a key DNA repair protein, the work suggests that therapies addressing metabolic reprogramming might help stabilize genomes in these cancers. The study underscores that fumarate hydratase plays a dual role—not just in metabolism but also in maintaining genome integrity—offering fresh insight into why its loss drives cancer development.